jusvinza, arthritis, reumatoid
Application of Jusvinza to patient as part of the expanded intervention study at Lucia Hospital. Photo: Courtesy of Alberto Alberteri, M.D.

Jusvinza application in patients with rheumatoid arthritis culminates

After the application of the ninth dose of Jusvinza to the third and last group of patients with moderately to severely active rheumatoid arthritis concluded in Holguin the expanded intervention study with this biotechnological product.

Jusvinza is a Cuban product designed for the treatment of autoimmune diseases, which began to be applied in this northeastern territory in September 2023.

According to Dr. Alberto Alberteris Rodríguez, the head of this study in Holguín who has been in charge of the research and follow-up of the patients: “So far the results have been encouraging for those who have benefited from this drug, since having effective treatments such as Jusvinza is fundamental in improving their quality of life. The work of researchers and specialists in this field is of vital importance to achieve advances in the treatment of this disease.”

“So this ninth dose marked the end of the application of the drug in this specific study. However, the research work continues continues as the team of professionals in charge of its application is getting ready for the evaluation of the patients in week 28 of the study, where it is expected that the results obtained in week 16 will be superior”.

Rheumatoid arthritis is a chronic inflammatory disease in which the immune system attacks its own tissues, which include the joints, either in the hands and feet.

Jusvinza is a biotechnological product made up of a molecule of 27 amino acids with an anti-inflammatory and immune response modulator effect, according to the also second degree specialist in Rheumatology.

At present, this product, as part of the modifications made to the Basic List of Medicines during the Basic List of Medicines during the current year, it was incorporated as one of the newly introduced drugs.

Jusvinza has been previously used, in addition to rheumatoid arthritis, in the pandemic stage of Covid-19 in patients with hyperinflammation, while its use has been proposed for conditions such as community pneumonia.

Leave a Reply

Your email address will not be published. Required fields are marked *

two × 3 =